Comedication Risk Factors for Cisplatin-Induced Hearing Loss in Pediatric Cancer Patients

A 2026 meta-analysis by Kim E. de Jagger synthesizes evidence from 27 studies involving 7007 pediatric cancer patients. The review identifies vincristine, furosemide, aminoglycosides, and vancomycin as comedications associated with an increased risk of cisplatin-induced hearing loss. The dataset is a PDF document summarizing the narrative review and meta-analysis results.

Use Cases

• Assessing drug interaction risks for cisplatin ototoxicity based on the identified comedications.
• Informing clinical trial design for pediatric cancer regimens by considering the meta-analysis findings.
• Supporting systematic literature reviews on adverse drug events in pediatric oncology.

Strengths

• Aggregates findings from 27 distinct studies.
• Includes quantitative risk estimates (odds ratios) for four specific drugs.
• Focuses on a clinically significant adverse event affecting 50-70% of cisplatin-treated children.

Limitations

• The primary data is a PDF summary; underlying patient-level data is not provided.
• The review notes heterogeneity among the included studies in design and quality.
• The dataset is small (337.4 KB), containing only the review document.

Provenance

Source

figshare

Collection Method

Narrative literature review and meta-analysis of studies from PubMed (Medline), EMBASE, and Cochrane CENTRAL.

Freshness

Last updated 2026-05-13.